Research projects
Start of main content
Synthetic nanoparticles as an innovative treatment for sepsis (SPRINT-4-SEPSIS)
19th national competition for scientific and technical research
Sepsis: Early Warning, Prevention and Treatment

Senior Researcher : Antonio Artigas Raventós
Research Centre or Institution : Instituto de Investigación e Innovación Parc Taulí (I3PT), Corporación Sanitaria i Universitaria Parc Taulí
Abstract
It is well established that mesenchymal stromal cells (MSC) through their paracrine activity, which is mediated, in part, by exosomes has a remarkable therapeutic effectiveness in regeneration and modulating the immune response.
We aim at developing a cell-free therapy based on the production of synthetic nanocapsules (NCs) encapsulating active components identified from MSC-derived exosomes cargo that will down-regulate inflammation, will assist the restoration of systemic immune homeostasis and improve the lung injury in a sepsis model.
During the second year of the project we have analized the protein and miRNA expresion profile of exosomes from non-activated and activated MSCs. Importantly, this analysis has revealed that pre-conditioning MSCs to a septic environment modifies the cargo of its exosomes, resulting in the appearance of proteins related to cell cycle regulation, cell proliferation and miRNAs with a key role on suppressing inflammation and enhancing immunoregulatory pathways.
Concerning the nanocarrier to deliver pre-selected exosomal components, we have developed new red fluorescent PLGA NCs with different surface charges. The performed in vitro studies showed that they are well preserved after cryo-storage for at least one month, are colloidally stable in tested culture and biological media and did not exhibit cytotoxic effects, even at very high concentrations, on two representative cell types in the pulmonary environment. In addition, we studied the NCs intracellular uptake confirming that the NCs are internalized by the 90% of the cells 4h after the treatment. In vivo studies demonstrated that our new carrier can be safely administered intratracheally, by inhalation and intravenously. Particularly, NCs are especially suitable as a pulmonary drug delivery system due to their satisfactory retention in lung tissue.
We believe that those first steps are very promising towards a cell-free therapeutic strategy for sepsis, identifying specific proteins and miRNAs that could be responsible for the exosomes therapeutic effect and by developing and characterizing a nanocarrier, that in the future, will make it an innovative and cell-free treatment for sepsis and lung injury related diseases.
Scientific Production |
|
---|---|
Magazine Articles | 2 |
Communications at national conferences | 4 |
Communications at international conferences | 3 |
-
Activities related
-
Projects related
-
News related
-
Publications related
-
27
Nov
2019
International Symposium Undiagnosed and rare diseases in children and adolescents: Translation to clinic and society Barcelona, Wednesday and Thursday, November 27 and 28, 2019 9:30 hours
-
11
Mar
2021
Jornada online Especialidad genética clínica: una urgencia en España ONLINE, Thursday, 11 March 2021, 19:00 hours
-
26
Sep
2022
Conference Terapia génica y celular avanzada… Más allá de la última frontera Madrid, Monday, 26 September 2022, 19:00 hours
- Risk Assesment of Bacterial Sepsis using multiomic and bioinformatics tools: an approach towards the Precision Medicine in Infectious Diseases 2018 Senior Researcher : María Teresa Coque González
- Extracellular vesicles biomarkers for the diagnosis and prognosis of post-surgical septic shock 2018 Senior Researcher : Eduardo Tamayo Gómez Research Centre or Institution : Hospital Clínico Universitario de Valladolid
- Molecular imaging of the infection by Clostridiodes difficile 2020 Senior Researcher : Beatriz Salinas Rodríguez Research Centre or Institution : Fundación para la Investigación Biomédica del Hospital Gregorio Marañón. Madrid
-
Eric D. Green: “La genómica debe integrarse en la medicina convencional”
Published on 03/12/2021

End of main content